[Efficacy and safety of Cortexin as additional therapy in patients with depressive disorder].

Schastnyy ED

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2026

PMID41782536DOI10.17116/jnevro202612602192PepBankPUB-41782536

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with depressive disorder, adjunctive Cortexin reduced depression severity more than basic antidepressant treatment alone at visit 3.
In plain wordsIn patients with depression, added Cortexin reduced depression severity more than antidepressant treatment alone.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
DecreaseMADRS depression severity at visit 3
Study
n = 98
Comparator
basic antidepressant treatment alone
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
10 mg once daily · intramuscular · 10 daysAs given in this study (human).
Source sentences
Summary
At visit 3, a significant reduction in depression severity (MADRS), an improvement in the quality of life of patients with depressive disorder (SASS), and a decrease in adverse events (UKU) were observed, with significant differences between the groups (p=0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The study involved 98 patients (56 women and 42 men) with a mean age of 44.0 (36.0; 52.0) years.
Summary · context
They were divided into 2 groups: Group 1 (n=48) received basic antidepressant treatment plus intramuscular Cortexin at a dose of 10 mg once daily (in the morning) for 10 days; Group 2 (n=50) received only basic antidepressant treatment.
Report a problemFND-4178253601
02HumanNon-randomized trialEfficacy outcome
In patients with depressive disorder, adjunctive Cortexin improved SASS-assessed quality of life more than basic antidepressant treatment alone.
In plain wordsIn patients with depression, added Cortexin improved quality of life more than antidepressant treatment alone.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseSASS quality of life at visit 3
Study
n = 98
Comparator
basic antidepressant treatment alone
Outcome group
Quality of life · Mental health and mood
Studied dose
10 mg once daily · intramuscular · 10 daysAs given in this study (human).
Source sentences
Summary
At visit 3, a significant reduction in depression severity (MADRS), an improvement in the quality of life of patients with depressive disorder (SASS), and a decrease in adverse events (UKU) were observed, with significant differences between the groups (p=0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The study involved 98 patients (56 women and 42 men) with a mean age of 44.0 (36.0; 52.0) years.
Summary · context
They were divided into 2 groups: Group 1 (n=48) received basic antidepressant treatment plus intramuscular Cortexin at a dose of 10 mg once daily (in the morning) for 10 days; Group 2 (n=50) received only basic antidepressant treatment.
Report a problemFND-4178253602
03HumanNon-randomized trialSafety outcome
In patients with depressive disorder, adjunctive Cortexin reduced UKU-assessed adverse events more than basic antidepressant treatment alone.
In plain wordsIn patients with depression, added Cortexin reduced adverse events more than antidepressant treatment alone.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
DecreaseUKU adverse events at visit 3
Study
n = 98
Comparator
basic antidepressant treatment alone
Outcome group
Adverse events · Whole body
Studied dose
10 mg once daily · intramuscular · 10 daysAs given in this study (human).
Source sentences
Summary
At visit 3, a significant reduction in depression severity (MADRS), an improvement in the quality of life of patients with depressive disorder (SASS), and a decrease in adverse events (UKU) were observed, with significant differences between the groups (p=0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The study involved 98 patients (56 women and 42 men) with a mean age of 44.0 (36.0; 52.0) years.
Summary · context
They were divided into 2 groups: Group 1 (n=48) received basic antidepressant treatment plus intramuscular Cortexin at a dose of 10 mg once daily (in the morning) for 10 days; Group 2 (n=50) received only basic antidepressant treatment.
Report a problemFND-4178253603
04HumanNon-randomized trialEfficacy outcome
In patients with depressive disorder, more patients receiving adjunctive Cortexin rated improvement as significant or substantial than with antidepressant treatment alone.
In plain wordsIn patients with depression, more rated improvement as significant or substantial with added Cortexin than with antidepressant treatment alone.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreasePatient-rated significant or substantial improvement
Study
n = 98
Comparator
basic antidepressant treatment alone
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
10 mg once daily · intramuscular · 10 daysAs given in this study (human).
Source sentences
Summary
By the end of the study, a significantly larger proportion of patients in the main group rated the improvement from therapy as «significant» and «substantial» (p=0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The study involved 98 patients (56 women and 42 men) with a mean age of 44.0 (36.0; 52.0) years.
Summary · context
They were divided into 2 groups: Group 1 (n=48) received basic antidepressant treatment plus intramuscular Cortexin at a dose of 10 mg once daily (in the morning) for 10 days; Group 2 (n=50) received only basic antidepressant treatment.
Report a problemFND-4178253604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.